Opioid moderatism and the imperative of rapprochement in pain medicine

Michael E Schatman1,2
Alexis Vasciannie3,4
Ronald J Kulich3,5

1Research and Network Development, Boston PainCare, Waltham, MA, USA; 2Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA; 3Department of Diagnostic Sciences, Tufts University School of Dental Medicine, Boston, MA, USA; 4Department of Biological Sciences, Northeastern University, Boston, MA, USA; 5Department of Anesthesia Critical Care and Pain Medicine, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA

A brief history of the “prescription opioid crisis”
Few would deny that the first decade of this millennium was marked by a “prescription opioid crisis” in the United States, characterized by overprescription and frank opiophilia. Although many have attempted to blame this crisis on a single cause, more thoughtful analysis has yielded numerous contributors to the onset and maintenance of the abuse crisis. Schatman,2,3 among others, has posited that health insurance carriers’ decision to discontinue coverage of interdisciplinary pain management programs left physicians without the most effective means of treating chronic pain, resulting in the consequence of turning to increased opioid prescribing. Dasgupta et al1 recently suggested that the pharmaceutical industry responded to this void by propagating not only long-acting opioids but forms that were ultra-rapid-acting, including dissolving strips and nasal sprays. They also noted that safety issues associated with non-opioid pain medications such as non-steroidal anti-inflammatory drugs and acetaminophen may have further fueled opioid prescribing. Perhaps the aggressive and fraudulent marketing of OxyContin as “nonaddictive” has been considered the primary culprit in the prescription opioid crisis,4 although other questionable industry behaviors such as kickback schemes,5 lucrative compensation for speaking as an incentive to prescribe,6 and promotion of off-label use7 have also been implicated as contributing to the prescription opioid conflict. In the late 1990s patient advocates began to encourage the assessment of pain as the “fifth vital sign”, and those most vehemently against opioids have gone so far as to suggest that pharmaceutical industry lobbying was responsible for the Joint Commission on Accreditation of Healthcare Organizations’ (JCAHO) advocacy for the institution of such.8 JCAHO’s proclamation has been indicted as creating a culture resulting in a marked increase in opioid prescription.9 Other causes to which the prescription opioid crisis has been attributed include unscrupulous physicians operating “pill mills”,10 unrealistic expectations of patients regarding complete relief of pain,11 state medical boards curtailing restrictions on prescribing opioids for noncancer pain,12 the Affordable Care Act’s provision requiring hospitals’ provision of patient satisfaction surveys that included satisfaction regarding pain relief,13 increased availability of prescription opioids without a prescription over the internet,14 and providers’ failures to adequately identify and monitor misuse and overuse.15 This list is far from exhaustive, with a recent assessment16 reporting that “The root causes of the modern opioid crisis are complex and traceable to at least 30 or more factors” (p. 943).
However, despite a lack of consensus, a recent analysis concluded that the prescription opioid crisis is over, replaced by an even more deadly epidemic of overdose deaths from heroin and illicit fentanyl and its analogs. This is consistent with the United States Food and Drug Administration’s data, which demonstrate a decrease in total opioid sales (as measured by morphine milligram equivalents [MME]) every year since 2010. Similar to the lack of consensus regarding the root cause(s) of the prescription opioid epidemic is that regarding the cause(s) of the precipitous decline in overall opioid prescribing over the past 8 years.

**Efforts to curb the “prescription opioid crisis”**

Some have opined that America’s “war on opioids” began a century and a half ago in response to injured Civil War veterans becoming dependent on morphine, with this dependence referred to as the “soldier’s disease.” When Congress passed the Harrison Act in 1914, its purpose was to prohibit recreational use of opioids, which had become rampant. However, in fact, a result of this legislation was what approximated the pendulum swinging toward the opioophobia that characterized the most recent prescription opioid crisis. By 2002, epidemiologic data suggested that 4.7% of US residents over the age of 12 had abused a prescription opioid during that year.

Although it is difficult to definitively identify the initial effort to curb overprescription of opioids in this millennium, it may have been the College on Problems of Drug Dependence’s commission of its Taskforce on Prescription Opioid Abuse in 2001 that marked the first concerted effort to address the nonmedical use and abuse of prescription opioids. They emphasized that “... the need to control and reduce abuse, diversion, and trafficking of opioid analgesics must be balanced against the need for physicians and patients to have access to licit opioids for the treatment of pain” (p. 216). However, as the decade progressed, the published literature became progressively less balanced, and the pendulum began to swing more strongly toward opioophobia. Prescribing guidelines of questionable quality were released by interventional pain societies, as they recognized an opportunity to increase their own market share of chronic pain patients by demonizing opioid analgesia.

Washington State’s Medical Director of workers compensation began his war on opioids in 2005, publishing a retrospective study in which he and his colleagues found a positive correlation between high-dosage opioids and overdose death in workers compensation patients. In 2007, a group that he led developed an “educational” opioid prescribing guideline, followed by a “recommended” guideline in 2010 and an updated guideline in 2015. Each iteration was more restrictive regarding its recommended arbitrary opioid limits or “triggers” than the previous one, and was based on “consensus” rather than “evidence”. Although these guidelines were promoted as “voluntary”, their “chilling effect” resulted in widespread fear among Washington physicians, thereby reducing prescribing.

As soon as the 2015 Washington State guideline was published, many of its authors began working with the United States Centers for Disease Control and Prevention (CDC) on its 2016 guideline, which was also touted as “voluntary”. However, even before it was released, concerns were expressed that its intention was to become de facto law: “In fact, the CDC imprimatur makes it more likely that these guidelines become de facto requirements through adoption by state health departments, professional licensing bodies or insurers.” Tragically, this is what appears to have happened, in state legislatures, state medical boards, and among both private and public insurers. State legislatures have already passed draconian legislation mandatorily limiting opioid dosing for acute pain, with no evidence of societal benefit. For example, Florida recently enacted a law that generally limits duration of opioid prescription for acute pain to 3 days, without regard for elderly, impoverished patients who may not have transportation to get new prescriptions as well as not being able to afford additional copays. Similar legislation was already in place in Kentucky. The law in Florida becomes potentially even more destructive, in that it requires that all prescribers take a 2-hour continuing education course on the law at each license renewal in order to maintain their controlled substance licenses. This type of overreaching legislation may discourage some physicians from prescribing controlled substances altogether. Although no state has yet passed legislation that limits MME below...
levels recommended by the CDC guideline, states are writing guidelines and laws that require prescribers to consult with a “pain specialist” in order to prescribe MME well below those recommended by the CDC guideline. Given the shortage of board-certified pain specialists and that primary care physicians are generally ill-equipped and poorly supported, this may pose a problem, particularly in rural and other underserved areas. Perhaps one of the best known of such laws is that of Indiana, stipulating that after 3 months of a mere 15 MME, a “trigger” necessitating that prescribers alter their standard prescribing practices goes into effect. Although there appears to be considerable “internet chatter” regarding individual state legislatures passing de jure laws creating “hard ceilings” for opioid MMEs, any such laws, at this point, are de facto rather than de jure. Unfortunately, anecdotally, patients in numerous states are being told by their physicians that they have to cut back their opioid dosages due to state laws requiring them to do so, which is inaccurate and disingenuous.

Another way in which state laws now potentially limit access to opioid analgesia is a subtler one, pertaining to Prescription Drug Monitoring Programs (PDMPs). Recently, the Kentucky PDMP began to identify any past illicit drug convictions within the past 5 years. Accordingly, if a legitimate pain patient had been convicted of a marijuana possession offense 5 years ago, his/her PDMP results would indicate such, and potentially reduce the likelihood of that patient receiving opioid analgesia, perhaps based more on stigma than on actual current risk.

Health insurers, on the other hand, are indeed mandating hard limits on MMEs for chronic pain, and this is causing considerable distress. One group of insurers that has been particularly short-sited in its recent policies is state-managed Medicaid programs, which are operated under federal guidelines. However, as they are managed by individual states, their policies, including those pertaining to opioids, vary dramatically from state to state. Although initially, some states’ Medicaid programs focused on limiting short-acting opioid units, the recently proposed law in Oregon essentially eliminating Medicaid coverage for any chronic opioid therapy for chronic noncancer pain is particularly oppressive. Specifically, the Oregon Health Authority’s Chronic Pain Task Force has proposed a 90-day limit on prescription opioids for certain chronic pain conditions for Medicaid recipients, and that those patients who have been receiving opioids for more than a year to be tapered off of them completely. The “consolation”, however, is that Oregon Medicaid would cover 30 sessions of “evidence-based” treatments in lieu of opioids. These treatments include complementary and alternative medicine approaches, the evidence-bases for most of which for a number of chronic pain conditions that will no longer be treated with opioids through Oregon Medicaid are hardly impressive.

Another health insurer/health care system that has mandated harsh decreases in opioid use over the past year is Veterans Affairs (VA) Medical Centers. Between 2012 and 2017, 99% of all VA facilities reduced their percentage of patients to whom opioids were prescribed with a decrease of 41% in the ratio of patients prescribed an opioid to those patients prescribed any medication. This can be compared to a 22% reduction in the number of opioid prescriptions in the general population between 2013 and 2017. While the VA has attempted to counteract the impact of this substantial reduction by developing interdisciplinary chronic pain management programs, limited funding has allowed for the development of only a small number of them, resulting in numerous veterans receiving inadequate analgesia with no adequate substitute treatment available. Although the efforts of for-profit, private insurers to reduce opioid prescribing have been less transparent, for the most part, a 2018 formulary change by Cigna has demonstrated that private insurers are now in the “business” of reducing opioid prescribing. Cigna switched its “preferred” brand of abuse-deterrent extended-release opioid to a newer drug, with a deal with the new manufacturer to encourage physicians to prescribe lower dosages of the medication that became a preferred drug on the formulary. Although health insurers’ policies on opioids have been questioned as merely tools for increased cost-containment and profitability, the impact of these changes on levels of oligoanalgesia has yet to be determined.

The result of the “war on prescription opioids” – “collateral damage”

A primary result of what has been both an evolution and a devolution in America’s opioid policy has been increased suffering for many for whom there are no other accessible options for their chronic pain other than opioid analgesia. For many years, the plight of these patients was ignored, with an emphasis on the far “sexier” “opioid epidemic”. However, well-respected academicians have been exposing the impact of the “opioid pendulum” on pain patient well-being over the past several years, with progressively more papers on the “new opioid crisis” of opophobia being published. For example, in 2013, Schatman and Darnall revived the Ethics Forum in Pain Medicine, with the initial article titled, “A pendulum swings awry: seeking the middle ground on
opioid prescribing for chronic non-cancer pain”.50 Shortly after its publication, Atkinson et al51 wrote an article on the “pendulum swinging too far”, noting the damage that was being done to patients. Subsequently, numerous articles on the topic have been written not only by pain specialists52–56 but by other health care professionals,57,58 including addiction medicine specialists59–61 and bioethicists.62,63 Mainstream media has finally begun to recognize the plight of patients with pain, with the number of articles written on the gravity of the situation progressively increasing.64–70 However, opio-phobia – as practiced in academic and community medical centers – continues to increase in scope and severity, thus promoting the passage of even more draconian legislation and the insurance industry’s further limitation of access to opioid analgesia to patients for whom there is no other adequate and accessible option. As a result, the plight of patients with chronic pain is at a modern-era height of severity, with no sign of the end of the “war on opioids” in which patients are the “collateral damage”.

Solving the dilemma
To this point, this analysis has focused on the history of the United States’ prescription opioid crisis, (at times misguided) efforts to end it, and the suffering that patients with pain have experienced as a result of these efforts. The remainder of this essay will focus on several strategies that will be imperative if the plight of the patient with chronic pain is to be eased. Doing so will require a widespread acceptance of “opioid moderatism”, which seems to be a stance that few in the pain world (patients, physicians, insurers, and legislators) are willing to consider. However, we are concerned that the “opioid wars” will continue to harm patients, physicians, and society broadly until a moderatist stance is shared by all the parties involved.

Provider responsibilities
Few would deny that only several years ago, opioids were severely overprescribed in the United States. Reckless overprescription is clearly inconsistent with aggressive risk mitigation, and is perhaps its antithesis. Although no single risk mitigation strategy is a panacea for opioid overuse, abuse, and diversion, practices such as medication agreements,71,72 consistent use of PDMPs,73–75 and urine drug toxicology (UDT)76–78 all have at least moderate evidence-bases for increasing prescription safety. However, the lack of use of these tools in many clinical settings in which pain is treated is disturbing. For example, despite the use of medication agreements being recommended in treatment guidelines for patients with chronic pain taking opioids,79 a recent study of such patients79 determined that only 46% were on an agreement. Currently, PDMP use is mandatory for prescribers in only 34 states,80 with rates of failure to consult with the PDMP before prescribing varying between these states. In the 16 states in which PDMP use is voluntary, rates of use also vary. A recent study of PDMP use in Florida81 (a state known in the past for “pill mills” and considered one of the most “problematic” states for opioid abuse and diversion82) indicated that only 31% of prescribers in the state were even registered to use the PDMP, and that pharmacists were actually querying the PDMP more frequently than physicians. UDT use has also been woefully low. For many years, it appeared to be linked closely to high levels of remuneration for physicians,83 with profiteering and kickback schemes involving both physicians and UDT labs rampant.84 Despite considerable disagreement between legislators, medical associations, and state medical boards regarding the optimal approach to UDT,85 it is apparent that it is underutilized in opioid management. Among the most troubling data on underutilization of UDT are from a 2012 study86 that determined that only 7% of patients prescribed opioids on multiple occasions at an HIV clinic underwent UDT. Similarly discouraging are results of a 2011 study of over 1,600 patients on chronic opioid therapy in which only 8% underwent UDT.87 Perhaps these two studies represent an extreme. Recent investigations of the prevalence of UDT use in patients receiving chronic opioid therapy suggest that although rates may be higher (eg, 32.8%,88 33%89) the determined prevalences do not approach the 2016 CDC guideline’s recommendation for universal use of UDT in treating chronic pain with opioids.33 It should be noted that opioid risk reduction initiatives can make a difference in the rate of UDT utilization, with a recent study finding that providers participating in such initiatives increased their UDT compliance from <15% to 50%, while those in control clinics increased only to 20%.90

The Boston PainCare model of opioid risk mitigation: a glimmer of hope?
We are concerned that a failure of clinicians to adequately mitigate risk (as demonstrated by the data presented above) has resulted in prescription opioids having essentially been “litigated away” – resulting in widespread opio-phobia and oligoanalgesia. Few argue for a return to patterns of reckless prescribing that was one of the root causes of the prescription opioid crisis. However, a more moderatist approach needs to be considered if the opioid pendulum is to ever find a safe yet humane resting place.
Boston PainCare is a community-based, tertiary chronic pain care facility that was founded by a group of anesthesiologists in 2007. Despite pain management’s reputation as operating primarily for financial incentives,91–96 Boston PainCare’s philosophy of integrated chronic pain care transcends what is being seen as the “new normal” in American pain medicine.97 One way in which this is being done is through extremely comprehensive yet patient-centered opioid risk mitigation. First, Boston PainCare is neither “pro-opioid” nor “anti-opioid”, but rather “pro-patient”. Boston PainCare’s mission is to restore the function and improve the quality of life of those suffering from chronic pain while reducing the overall financial and social cost associated with chronic pain treatment. The facility embraces a patient-centered interdisciplinary model of care that involves collaboration between providers. The center employs functional and behavioral interventions as the core treatments to achieve its mission. Ancillary treatments (such as medication management) are used to facilitate core treatment engagement while post-treatment compliance is promoted through patient education and self-advocacy. Integration of care is key to the success of Boston PainCare’s treatment model and is supported through the use of customized electronic health record (EHR) technologies. Data analysis (both individual and aggregate) is employed to monitor individual progress toward goals, monitor and improve the efficacy of the center’s treatment algorithms, and determine the best practice approaches through examination of population-based data. EHR customization allows for the early identification and expedient analysis of medication aberrancy data used by clinicians to develop treatment plans (eg, opioid reduction/elimination), identify interventions needed to end the aberrancy (eg, behavioral modification), initiate appropriate referrals (eg, addiction intervention, psychiatric treatment), and when necessary, engage local, state, and federal law enforcement.

Given the chilling effect of media reports, increased regulatory and/or legal sanctions, and the CDC’s continued exaggeration of prescription opioid mortality,17 patients with intractable chronic pain for whom there are no other effective and accessible options can no longer necessarily find health care practitioners who will provide them with ongoing opioid therapy. As a result, Boston PainCare is referred many “inherited” or “legacy” patients, with the patient expectation of receiving opioid analgesia. The frequency and challenges of these scenarios have been documented in the literature.98–100 However, as Boston PainCare considers chronic opioid therapy an ancillary treatment to facilitate functional and behavioral interventions and engagement, these new patients are not necessarily considered appropriate candidates for chronic opioid therapy – based on medical, functional, and behavioral evaluations and risk assessments. From the initiation of treatment, patients are informed that chronic opioid therapy, if otherwise appropriate, is contingent upon making functional gains and/or maintaining their functional capacities. The goal of opioid treatment is an individualized one, that is, tapering dosages to levels that maximize both safety and function in each individual patient. This stance is consistent with the recent literature that questions whether analgesia is and by itself should be considered an appropriate “ends” of pain medicine.101,102 All patients at Boston PainCare sign treatment consents, and those who are enrolled in the facility’s medication management program sign opioid agreements on an annual basis. Not only is the Massachusetts PDMP checked on a regular basis, but the PDMPs from the other New England states and New York are consulted as well. UDT is performed at every appointment for each patient prescribed opioids at the facility using a semiquantitative immunoassay machine that produces results that make the necessity of expensive confirmatory testing rare. The testing is performed in-house during the patient’s appointment, and the clinician has the results before seeing the patient. Although some have contended that certain physicians engage in urine drug overtesting based on profit motivation,78 the facility charges for only what is considered medically necessary by the insurance carrier. This is done in the purest spirit of opioid risk mitigation, the purpose of which is to protect individual patients as well as society, generally.

Patients are considered for the center’s Medication Management Program based on thorough medical, functional, and behavioral evaluations and risk assessments. For patients who are accepted into the program, Boston PainCare has created five distinct tiered medication care plans that provide varying levels of services, monitoring, and support based on the risks and needs of the individual patient. Patients on chronic opioid therapy at Boston PainCare fall into four levels of monitoring. Certain patients are on a PRN opioid regimen, with enrollment in this program requiring an absence of aberrant behaviors in conjunction with the need for less than daily use of opioid medication. Those receiving chronic opioid therapy deemed to be at the lowest level of risk based on history, psychosocial risk factors, and a lack of aberrancy are seen monthly through the Medication Management Program. Patients at a higher level of risk are seen every other week in the program, in which behavioral services are highly recommended. The majority of the patients in this program receive behavioral services on a regular basis. Finally, those
patients determined to be at “significant risk” for either medication misuse or whose behaviors are suggestive of a possible undiagnosed substance abuse disorder are enrolled in the Medsafe program. Medsafe is an 8-week care plan in which the goal is to either end the pattern of aberrant behavior through medical and behavioral treatments or to identify the presence of a disorder (ie, substance use disorder, significant psychiatric condition, and so on) that may require treatment external to Boston PainCare. These patients are seen weekly for their prescribing visits and are also engaged in frequent, mandatory behavioral treatments. Failure to “graduate” from the Medsafe program will result in referral to an addiction medicine program, as the facility’s philosophy is that while there may be a potential benefit to opioid therapy, continuing with such would be inappropriate when the risks of harm outweigh its potential benefit.

Although some may see Boston PainCare’s comprehensive, integrated approach as being overly paternalistic, the facility’s philosophy is that for some patients, ongoing opioid therapy is the only viable and accessible treatment—and needs to remain so. However, the patient’s “right” to be treated with opioids is contingent upon adherence. Furthermore, efforts are made to taper all patients down to safer dosages, with a motivational interviewing approach in conjunction with psychoeducational intervention resulting in great success in terms of helping patients understand that “less may be more”. Perhaps the greatest attestation to the facility’s approach may be that for 11 years, thousands of patients have been treated with chronic (often high-dosage) opioid therapy—without Boston PainCare’s knowledge of a single overdose death while in the program.

Rapprochement
As has been discussed above, the “opioid wars” between those who are “anti-opioid” and those who are equally “pro-opioid” have resulted in patients with intractable chronic pain becoming the collateral damage in the conflict, with the extent of the damage seemingly devolving from patient suffering to the tragedy of overdose deaths due to patients involuntarily tapered from prescription opioids seeking stronger, illicit opioids. A review of social media, particularly Twitter, indicates a progressively harsher level of discourse between patients with pain along with pain patient advocates and those that they perceive to be the cause of their suffering. Yet, many health care providers who consider themselves opioid moderatists are beginning to reach out to those considered to be anti-opioid—with the olive branch generally being accepted, and the level of discourse improving. As moderatists believe that those seen as anti-opioid share their goal of improving the quality of pain care in the United States, collaborations are being proposed. Key opinion leaders can be found on both sides of the “opioid argument”, and seeking a middle-ground together will likely to be essential in creating a national opioid policy that focuses on opioids not as a first-line treatment of chronic pain, yet as a tool that society cannot afford to eradicate from providers’ pain management armamentaria. Excellent examples of such are recent studies and articles on improving the safety and efficacy of compassionate and (ideally) voluntary opioid tapers. Furthermore, the authors of this article have been involved firsthand in efforts to create collaborations between all sides of the opioid argument, recognizing that only a complex solution to a very complicated problem will ever result in the commonly held goal of improved pain care and safety. We are particularly encouraged by a recent paper spearheaded by Dr Beth Darnall on the need for action against forced opioid tapering, as the signatories included over 100 key opinion leaders in pain and addiction medicine, patient advocacy, and bioethics whose positions have recently ranged from radically pro-opioid to radically anti-opioid—with a surprising number embracing a moderatist position.

Summary and conclusion
The history of the prescription opioid crisis in the United States is a complex and discouraging one. However, on a positive note, we opine that the “crisis” of overprescription of the previous decade is now over, although has been replaced by a crisis consisting of opiophobia, oligoanalgesia, and progressive increases in the use of far more deadly illicit opioids by patients left without an adequate plan for pain relief and improvement of quality of life. As is far too common in American society, efforts to identify the primary culprit for the crisis of the past have focused on individual players and policies rather than recognizing that it was due to an unfortunate confluence of factors. Almost as old as the prescription opioid crisis itself has been efforts to quell it—some of which have benefited society, others of which have resulted in the “double effect” of reducing prescription opioid availability and deaths while perhaps contributing to the substantial increase in overall opioid mortality though its contribution to the exponentially increasing illicit opioid crisis—which indeed now constitutes an epidemic.

As the perhaps unintended consequence of the 2016 CDC guideline, opioid analgesia runs the risk of essentially being legislated away. While this process may indeed be beneficial in terms of reducing prescription opioid mortality, it has been
accompanied by considerable suffering among chronic pain patients being denied opioid analgesia, even in cases in which opioids have helped them to become more functional. Furthermore, the process has contributed to the illicit opioid crisis that is resulting in considerably more mortality than was ever due to prescription opioids.112 Accordingly, we posit that draconian laws and policies of legislative and regulatory agencies need to be replaced by increased prescriber responsibility, such as that practiced at Boston PainCare for more than the past decade. Finally, the numerous stakeholders in the opioid wars need to continue to work toward rapprochement, recognizing that many of the leading players in the opioid wars are key opinion leaders—all of whom have much to contribute to finding a solution to this unprecedented social problem. Without such cooperation, individual and societal suffering will only continue to increase, which is certainly not the goal of any of the players involved.

Disclosure

Dr Schatman serves as a consultant with Kaleo Pharma. The authors report no other conflicts of interest in this work.

References

1. Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182–186.
2. Schatman ME. The role of the health insurance industry in perpetuating suboptimal pain management. Pain Med. 2011;12(3):415–426.
3. Schatman ME. The demise of interdisciplinary chronic pain management and its relationship to the scourge of prescription opioid diversion and abuse. In: Peppard J, Coleman J, Dineen KK, Ruggles A, editors. Pain and Prescription Drug Diverion: Healthcare, Law Enforcement, and Policy Perspectives. New York: Oxford University Press; 2018:205–218.
4. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221–227.
5. US Attorney’s Office District of Massachusetts. Pharmaceutical executives charged in racketeering scheme. Available from: https://www.justice.gov/usao-ma/pr/pharmaceutical-executives-charged-in-racketeering-scheme. Accessed June 28, 2018.
6. Hadland SE, Krieger MS, Marshall BDL. Industry payments to physicians for opioid products, 2013–2015. Am J Public Health. 2017;107(9):1493–1495.
7. Burns SM, Cunningham CW, Mercer SL. Dark classics in chemical neuroscience: fentanyl. ACS Chem Neurosci. 2018;9(10):2428–2437.
8. Franklin GM; American Academy of Neuroscience. Opioids for chronic noncancer pain: a position paper of the American Academy of Neuroscience. Neurology. 2014;83(14):1277–1284.
9. Mehandile AW, Goldman MP, Mehandile RP. Opioid overdose pain syndrome (OOPS): the story of opioids, promethazine unheard. J Opioid Manag. 2013;9(6):421–438.
10. Pardo B. Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction. 2017;112(10):1773–1783.
11. Peterson BL. Letter from the name president. Acad Forensic Pathol. 2017;7(1):viii–ix.
12. Mancikantl L, Huhn S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–ES38.
13. Fischer A. Tough love: why patients should change physician expectations. Ann Health Law. 2013;25:97–108.
14. Forman RF. Availability of opioids on the Internet. JAMA. 2003;290(7):889.
15. Deyo RA, Smith DH, Johnson ES, et al. Opioids for back pain patients: primary care prescribing patterns and use of services. J Am Board Fam Med. 2011;24(6):717–727.
16. Madras BK. The President’s Commission on combating drug addiction and the opioid crisis: origins and recommendations. Clin Pharmacol Ther. 2018;103(6):943–945.
17. Schatman ME, Ziegler SJ, Management P. Pain management, prescription opioid mortality, and the CDC: is the devil in the data? J Pain Res. 2017;10:2489–2495.
18. United States Food and Drug Administration. FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and price trends; March 1, 2018. Available from: https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM598899.pdf. Accessed June 26, 2018.
19. Courtwright DT. Dark Paradise: Opiate Addiction in America Before 1940. Cambridge, MA: Harvard University Press; 1982.
20. Trefebach A. The Heroin Solution. New Haven, CT: Yale University Press; 1981.
21. Nixon R. Special Message to the Congress on Drug Abuse Prevention and Control; June 17, 1971. Available from: http://www.presidency.ucsb.edu/ws/?pid=3048. Accessed June 28, 2018.
22. Singer JA. Physicians face moral dilemma in conscription on war on drugs. Reason; March 23, 2016. Available from: http://reason.com/archives/2016/03/23/physicians-face-moral-dilemma-in-conscri. Accessed June 28, 2018.
23. Dílicher AJ. Damned if they do, damned if they don’t: the need for a comprehensive public policy to address the inadequate management of pain. Ann Health Law. 2004;13(1):81–144.
24. Rich BA. A prescription for the pain: the emerging standard of care for pain management. William Mitchell Law Rev. 2000;26(1):1–91.
25. Substance Abuse and Mental Health Services Administration. Overview of Findings from the 2002 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2003.
26. Zacy C, Bigelow G, Compton P, Foley K, Uguchi M, Sannerud C. College on Problems of Drug Dependence Taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69(3):215–232.
27. Trescott AM, Boswell MV, Atueli SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1):1–39.
28. Trescott AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional pain physicians’ (ASIPP) guidelines. Pain Physician. 2008;11(2 Suppl):S5–S62.
29. Franklin GM, Mai J, Wickizer T, Turner JA, Fulton-Kehoe D, Grant L. Opioid dosing trends and mortality in Washington state workers’ compensation, 1996–2002. Am J Ind Med. 2005;48(2):91–99.
30. Washington State Agency Medical Directors’ Group. Interagency guideline on prescribing opioids for pain. 3rd Edition; June 2018.
31. Washington State Agency Medical Directors’ Group. Interagency guideline on pain management and its relationship to the scourge of prescription opioid overdose; 2010 update. Available from: http://www.dli.mn.gov/PDF/references/A16_WA_opioid_guideline.pdf. Accessed July 1, 2018.
32. Washington State Agency Medical Directors’ Group. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational pilot to improve care and safety with opioid treatment; March 2007.
33. Washington State Agency Medical Directors’ Group. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational pilot to improve care and safety with opioid treatment; March 2007. Available from: http://www.dli.mn.gov/PDF/references/A16_WA_opioid_guideline.pdf. Accessed July 1, 2018.
34. Washington State Agency Medical Directors’ Group. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational pilot to improve care and safety with opioid treatment; March 2007. Available from: http://www.dli.mn.gov/PDF/references/A16_WA_opioid_guideline.pdf. Accessed July 1, 2018.
33. Schatman M, Webster L. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. J Pain Res. 2015;8:153–158.

34. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.

35. Hansen CW. American cancer Society cancer action network letter to the United States centers for disease control and prevention; October 1, 2015. Available from: https://www.acscan.org/sites/default/files/ACSCAN_Comments_CDC_Opioid_Guidelines_Final.pdf. Accessed July 1, 2018.

36. Controlled substances, Florida HB 21 (2018), 2018-13. Available from: http://www.floridahouse.gov/Sections/Bills/billsdetail.aspx?BillId=60136. Accessed July 3, 2018.

37. KRS 218:205A; 2017. Available from: http://www.lrc.ky.gov/statutes/statute.aspx?id=6893. Accessed July 3, 2018.

38. Schottenfeld JR, Waldman SA, Gluck AR, Tobin DG. Pain and addiction in specialty and primary care: the bookends of a crisis. J Law Med Ethics. 2018;46(2):220–237.

39. Pan K, Blankley AJ, Hughes PJ. An examination of opioid prescription for Medicare Part D patients among family practice prescribers. Fam Pract. Epub 2018 Sep 19.

40. Indiana Administrative Code, Title 844, 5-6-3 triggers for imposition of requirements; exemptions. Available from: http://www.in.gov/legislative/iaac/iaac_title?act=844. Accessed July 9, 2018.

41. Kentucky Cabinet for Health and Family Services Office of the Inspector General, Drug Enforcement and Professional Services Branch. Kentucky Controlled Substances Act, revised January, 2018. Available from: https://chfs.ky.gov/agencies/oiag/dae/dpph/Documents/2018ControlledSubstanceStatuteHandbook.pdf. Accessed August 3, 2018.

42. Colorado Department of Health Care Policy & Financing. Communication regarding clarification of new short-acting oral opioid policy; August 25, 2014. Available from: https://www.colorado.gov/pacific/sites/default/files/KCS/CSHP%20Cabinet%20Minutes%208-25-14.pdf. Accessed August 3, 2018.

43. Oregon Health Authority Chronic Pain Task Force. Minutes; June 7, 2018. Available from: https://chfs.ky.gov/agencies/oiag/dae/dpph/Documents/2018ControlledSubstanceStatuteHandbook.pdf. Accessed August 3, 2018.

44. Ju ZY, Wang K, Cui HS, et al. Acupuncture for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;12:CD012057.

45. Lauche R, Cramer H, Häusser W, Dobos G, Langhors J. A systematic review of summaries for complementary and alternative therapies in the treatment of the fibromyalgia syndrome. Evid Based Complementary Altern Med. 2015;2015(5):1–13.

46. United States Department of Veterans Affairs Office of Public and Intergovernmental Affairs. VA becomes first hospital system to release opioid prescribing rates. Available from: https://www.va.gov/opapressrel/pressrelease.cfm?id=3997. Accessed July 31, 2018.

47. American Medical Association. American Medical association opioid Task Force 2018 progress report. Available from: https://www.ama-assn.org/en/ama-opioid-task-force-2018-progress-report.

48. Curley B. What if insurance companies stopped covering opioid prescriptions? Healthline; October 18, 2017. Available from: https://www.healthline.com/health-news/what-if-insurance-companies-stopped-covering-opioid-prescriptions#1. Accessed July 31, 2018.

49. Schatman ME. The American chronic pain crisis and the media: about time to get it right? J Pain Res. 2015;8:885–887.

50. Schatman ME, Darnall BD. A pendulum swings awry: seeking the middle ground on opioid prescribing for chronic non-cancer pain. Pain Med. 2013;14(5):617–620.

51. Atkinson TJ, Schatman ME, Fudin J. The damage done by the war on opioids: the pendulum has swung too far. J Pain Res. 2014;7:265–268.

52. Lynch M. The opioid pendulum and the need for better pain care. Pain Med. 2016;17(7):1215–1219.

53. Lipman AG. Evolving government policy on opioid availability and use is a double-edged sword. J Pain Palliat Care Pharmacother. 2016;30(2):88–90.

54. Gled SA. The other victims of the opioid epidemic. N Engl J Med. 2017;376(22):2101–2102.

55. Gallagher R. New category of opioid-related death. Can Fam Physician. 2018;64(2):95–96.

56. Darnall BD, Juurlink D, Kerns RD, et al. International Stakeholder Community of Pain Experts and Leaders call for an urgent action on forced opioid tapering. Pain Med. Epub 2018 Nov 29.

57. Henry SG, Holt ZB. Frustrated patients and fearful physicians. J Gen Intern Med. 2017;32(2):148–149.

58. Rose ME. Are prescription opioids driving the opioid crisis? Assumptions vs facts. Pain Med. 2018;19(4):793–807.

59. Kertesz SG, Gordon AJ. A crisis of opioids and the limits of prescription control: United States. Addiction. 2019;114(1):169–180.

60. Coerceri G, Katzman J, Duhigg D. Controlling the swing of the opioid pendulum. N Engl J Med. 2018;378(8):691–693.

61. Kertesz SG, Manhapra A. The drive to taper opioids: mind the evidence, and the ethics. Spinal Cord Ser Cases. 2018;4(1):64.

62. Rothstein MA. The opioid crisis and the need for compassion in pain management. Am J Public Health. 2017;107(8):1253–1254.

63. Carvalho AS, Martins Pereira S, Jácomo A, et al. Ethical decision making in pain management: a conceptual framework. J Pain Res. 2018;11:967–976.

64. Ramsey L. ‘We’re treated like drug addicts’: as America fights opioid addiction, the healthcare system is failing people who live with chronic pain. Business insider; January 28, 2018. Available from: https://www.businessinsider.com/people-with-chronic-pain-during-opioid-crisis-2018-1. Accessed August 7, 2018.

65. Hoffman J. Medicare is cracking down on opioids. Doctors fear pain patients will suffer. New York Times; March 27, 2018. Available from: https://www.nytimes.com/2018/03/27/health/medicare-limits.html. Accessed August 7, 2018.

66. Zeltner B. Suffering and abandoned: chronic pain patients cut off in the opioid era. Cleveland Plain Dealer, updated April 23, 2018. Available from: https://www.cleveland.com/healthltf/index.ssf/2018/04/suffering_and_abandoned_chronic.html. Accessed August 7, 2018.

67. Burling S. Lost in the battle to create fewer new patients addicted to opioids: Longtime pain patients. Philadelphia Inquirer, May 24, 2018. Available from: http://www.philly.com/philly/health/addiction/chronic-pain-patients-opioid-prescribing-limits-medicare-20180524.html. Accessed August 7, 2018.

68. O’Donnell J, Chu J. Chronic pain patients, overlooked in opioid crisis, getting new attention from top at FDA. USA Today, updated July 3, 2018. Available from: https://www.usatoday.com/story/news/politics/2018/07/02/chronic-pain-patients-needs-ignored-opioid-epidemic/727015002/. Accessed August 7, 2018.

69. Kaiser Health News. Patients with chronic pain caught in opioid-prescription debate. Chicago Sun Times, August 6, 2018. Available from: https://www.chicagotribune.com/news/south-side/ct-chicago-sun-times-chronic-pain-opioids-20180529/.

70. Erlingsdottir I. Counterpoint: it’s not the prescription opioids that are the problem. Minneapolis Star Tribune, August 8, 2018. Available from: https://www.startribune.com/counterpoint-it-s-not-the-prescription-opioids-that-are-the-problem/490403171/. Accessed August 8, 2018.

71. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to help limit opioid abuse? JAMA. 2011;306(20):2258–2259.
Dovepress

Schatman et al

Journal of Pain Research

Publish your work in this journal

The Journal of Pain Research is an international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication.

Submit your manuscript here: https://www.dovepress.com/testimonials.php

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

74. Green TC, Mann MR, Bowman SE, et al. How does use of a prescription monitoring program change medical practice? Pain Med. 2012;13(10):1314–1323.

75. Finley EP, Garcia A, Rosen K, Mcgeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):420.

76. Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9(2):123–129.

77. Matteliano D, Chang YP. Describing prescription opioid adherence among individuals with chronic pain using urine drug testing. Pain Manag Nurs. 2015;16(1):51–59.

78. Wiseman LK, Lynch ME. The utility of universal urinary drug screening in chronic pain management. Can J Pain. 2018;2(2):37–47.

79. Kay C, Wozniak E, Ching A, Bernstein J. Pain agreements and healthcare utilization in a Veterans Affairs primary care population: a retrospective chart review. Pain Ther. Epub 2018 May 11.

80. Prescription Drug Monitoring Program Training and Technical Assistance Center. PDMP mandatory enrollment of prescribers and Dispensers, April 20, 2018. Available from: http://pdpnassist.org/pdf/Mandatory_Enrollment_20180417a.pdf. Accessed August 14, 2018.

81. Delcher C, Wang Y, Young HW, 2nd, Goldberger BA, Schmidt S, Reisfield GM. Trends in Florida’s prescription drug monitoring program registration and utilization: implications for increasing voluntary use. J Opioid Manag. 2017;13(5):283–289.

82. Rigg KK, March SJ, Inciardi JA. Prescription drug abuse and diversion: role of the pain clinic. J Pain Issues. 2010;40(3):681–701.

83. Collen M. Profit-driven drug testing. J Pain Palliat Care Pharmacother. 2012;26(1):13–17.

84. Mahajan G. Role of urine drug testing in the current opioid epidemic. Anesth Analg. 2017;125(6):2094–2104.

85. Schulte F, Lucas E. Liquid gold: pain doctors soak up profits by screening for urine drugs. Kaiser Health News, November 6, 2017. Available from: https://khn.org/news/liquid-gold-pain-doctors-soak-up-profits-by-screening-urine-for-drugs/. Accessed August 16, 2018.

86. Önen NF, Barrette EP, Shacham E, Taniguchi T, Donovan M, Overton ET. A review of opioid prescribing practices and associations with repeat opioid prescriptions in a contemporary outpatient HIV clinic. Pain Pract. 2012;12(6):440–448.

87. Starrels JL, Becker WC, Weiner MG, Li X, Heo M, Turner BJ. Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med. 2011;26(9):958–964.

88. Zgierska AE, Vidaver RM, Smith P, et al. Enhancing system-wide implementation of opioid prescribing guidelines in primary care: protocol for a stepped-wedge quality improvement project. BMC Health Serv Res. 2018;18(1):415.

89. Chaudhary S, Compton P. Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain. Subst Abus. 2017;38(1):95–104.

90. Sherman KJ, Walker RL, Saunders K, et al. Doctor-patient trust among chronic pain patients on chronic opioid therapy after opioid risk reduction initiatives: a survey. J Am Board Fam Med. 2018;31(4):578–587.

91. Taylor ML. The impact of the “business” of pain medicine on patient care. Pain Med. 2011;12(5):763–772.

92. Perret D, Rosen C. A physician-driven solution—the Association for Medical Ethics, the Physician Payment Sunshine Act, and ethical challenges in pain medicine. Pain Med. 2011;12(9):1361–1375.

93. Schatman ME. Physician complicity in the transformation of pain medicine from a “profession” to a “business”: strategies for reversing a growing trend. Pain Med. 2012;13(9):1149–1151.

94. Epstein N. Unnecessary multiple epidural steroid injections delay surgery for massive lumbar disc: case discussion and review. Surg Neurol Int. 2015;6(15):383–387.

95. Peña JA, Mencilly PA. Investigating and prosecuting opioid diversion and tampering cases involving medical professionals and institutional healthcare providers. US Attorneys Bull. 2016;64:115–144.

96. Patel AS. The business of pain medicine in the rehabilitation patient. In: Carayannopoulos A, editor. Comprehensive Pain Management in the Rehabilitation Patient. Cham: Springer International Publishing AG; 2017:935–948.

97. Schatman ME. A glimmer of hope in American Pain medicine? J Pain Res. 2016;9:509–513.

98. Grini Z. The inherited chronic pain patient. Aust Fam Physician. 2016;45(12):868–872.

99. Owston CL. The inherited patient on opioids: a challenge for primary care clinicians. JAAPA. 2016;29(10):37–43.

100. Krashin D, Murinova N, Sullivan M. Challenges to treatment of chronic pain and addiction during the “opioid crisis”. Curr Pain Headache Rep. 2016;20(12):65.

101. Ballantyne JC, Sullivan MD. Intensity of chronic pain – the wrong metric? N Engl J Med. 2015;373(22):2098–2099.

102. Sullivan MD, Ballantyne JC. Must we reduce pain intensity to treat chronic pain? Pain. 2016;157(1):65–69.

103. Nickerson JW, Attaran A. The inadequate treatment of pain: collateral damage from the war on drugs. PLoS Med. 2012;9(1):e1001153.

104. Schatmanne, Darnall BD. A practical and ethical solution to the opioid scheduling conundrum. J Pain Res. 2014;7:1–3.

105. Carr DB. “Care” without compassion – the eight social sin? Pain Med. 2016;17912:2153–2154.

106. Payne R. Opioid treatment agreements repurposed—but who monitors the monitors? Hastings Cent Rep. 2017;47(3):36–37.

107. Carroll JJ, Rich JD, Green TC. Reducing collateral damage in responses to the opioid crisis. Am J Public Health. 2018;108(3):349–350.

108. Matthias MS, Johnson NL, Shields CG, et al. “I’m not gonna pull the rug out from under you”: patient-provider communication about opioid tapering. J Pain. 2017;18(11):1365–1373.

109. Darnall BD, Ziadni MS, Stieg RL, Mackey IG, Kao MC, Flood P. Patient-centered prescription opioid tapering in community outpatients with chronic pain. JAMA Intern Med. 2018;178(5):707–708.

110. Schatman ME, Dibenedetto DJ, Kulich RJ. Voluntary opioid tapering—barriers to delivering care. JAMA Intern Med. 2018;178(6):874–875.

111. Dibenedetto DJ, Wawrzyniak KM, Finkelman M, et al. Relationships between opioid dosing, pain severity, and disability in a community-based chronic pain population: an exploratory retrospective analysis. Pain Med. Epub 2019 Jan 17.

112. Kertesz SG. Turning the tide or riptide? The changing opioid epidemic. Subst Abus. 2017;38(1):3–8.